During this monitoring period, only one corporate development related to Boston Scientific was recorded in the Asia-Pacific region. The company announced a global restructuring program aimed at cutting costs and improving efficiency, expecting to incur $700 to $800 million in related charges and achieve $500 million in annual pre-tax savings. Despite beating Q2 estimates, it lowered its full-year outlook due to competitive pressures, causing its shares to fall over 5% after the news.
- Boston Scientific launched a global restructuring involving layoffs, expecting $700-$800 million in costs to achieve $500 million in annual pre-tax savings.
- The company reported Q2 revenue of $5.44 billion and EPS of $0.86, beating estimates, but trimmed its full-year outlook due to competitive dynamics.
- Shares of Boston Scientific initially rose then fell over 5% after the restructuring announcement.